Neurocrine Biosciences, Inc. (NBIX), Monday announced interim data of KINECT-HD2 study of Ingrezza capsules for the long-term treatment of adults with chorea associated with Huntington's disease, a hereditary progressive neurodegenerative disorder.
During the ongoing open-label study, Ingrezza improved the condition as early as Week 2 and efficacy was sustained from Week 8.
The company noted that at Week 104, symptoms were reported to be 'much improved' or 'very much improved' in 75.9 percent of participants based on self-report and 73.6 percent of participants based on clinician assessment.
Currently, Neurocrine's stock is trading at $115.26, up 0.17 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.